<DOC>
	<DOCNO>NCT02589249</DOCNO>
	<brief_summary>The purpose 12-week , prospective study determine effect oral supplementation AyuFlex® ( over-the-counter dietary supplement ) joint mobility , joint comfort functional capacity healthy overweight subject .</brief_summary>
	<brief_title>The Effect AyuFlex® Supplementation Joint Health</brief_title>
	<detailed_description>This interventional study 12-week , randomize , double-blind , placebo dose-response control clinical trial ( 3 parallel group ) male female subject without active osteoarthritis knee recruit single investigational center U.S. A two-week placebo lead-in period precede study enhance statistical power . One-hundred five ( 105 ) overweight , apparently healthy subject , pre-screened use health history questionnaire , vital sign , blood work standardize low extremity exercise performance test randomize one three group 84 day : placebo , AyuFlex1 ( 500 mg/d ) AyuFlex2 ( 1000 mg/d ) . AyuFlex organic , non-GMO , over-the-counter joint health product derive edible fruit Terminalia chebula .</detailed_description>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>Healthy male female volunteer &gt; 35 &lt; 70 year age . Nonsmoker . Body Mass Index ( BMI ) great 30 kg/m2 less 45 kg/m2 screening . Willing maintain current background dietary physical activity pattern throughout study period . Knee joint : No knee joint discomfort rest . Experience knee joint discomfort activity exercise within last 2 week least 30 mm 100mm VAS rating `` knee discomfort activity exercise time last 3 week '' . Must achieve rating least 30mm 100mm VAS point throughout standardize low extremity exercise performance screen test ( Screening test = 3 set 1012 repetition seat knee extension machine + 3minute walk test maximal walk velocity ) . Nonpregnant , nonlactating female agree use effective contraceptive method throughout course study . Females childbearing potential must agree use one follow acceptable birth control method : 1 . Surgically sterile ( hysterectomy bilateral oophorectomy ) ; 2 . Surgically sterile ( bilateral tubal ligation surgery least 6 week prior study initiation ) ; 3 . Intrauterine device ( IUD ) place least 3 month ; 4 . Abstinence ( sexual intercourse ) ; 5 . Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; 6 . Vasectomized partner . Able understand study procedure provide sign informed consent , authorize release relevant health information study investigator . Normally active otherwise judge good health basis medical history physical examination . Females childbearing potential must negative urine pregnancy test screening . Subjects establish diagnosis inflammatory joint disorder osteoarthritis per ACR ( American College Rheumatology ) guideline . Currently take , chronic use within 30 day antiinflammatory supplement , Boswellia , Curcumin , Omega3 fatty acid , Glucosamine , Chondroitin , MSM , Collagen supplement type . Daily use NSAIDs ( nonsteroidal antiinflammatory drug ) ; however , daily use 81 mg aspirin ( &gt; 81 mg ) cardioprotection allow . Upon physical screen medical staff , subject sign overt nutrient deficiency metabolic abnormality anemia . This also need include screening assessment . Subjects history knee hip joint replacement surgery , hip back pain interferes walk exercise test utilized throughout study . Glucocorticoid ( Corticosteroid ) injection , hyaluronic acid injection , prolotherapy , PRP ( platelet rich plasma ) injection , bone marrow regenerative injection affect knee within 6 month prior enrollment study . Individual recent illness condition ( within 6 month screen ) Investigator believe would interfere ability provide inform consent , comply study protocol , might confound interpretation study result put person undue risk . Known suspect pregnancy , plan pregnancy , lactation . If subject treat psychiatric illness hospitalize within past year , upon PI discretion , exclude study . History allergic reaction know sensitivity Terminalia chebula chemically related botanical/ herbal product supplement . Any food allergy , intolerance , restriction special diet , opinion Investigator , could contraindicate subject 's participation study . Vital sign abnormality ( seat , rest systolic blood pressure low 90 high 150 mmHg , diastolic blood pressure low 50 high 100 mmHg , heart rate less 50 110 bpm ) screening . History clinically significant gastrointestinal disorder , ( eg , inflammatory bowel disease ) , presence gastrointestinal pathology , persistent gastrointestinal symptom ( eg , diarrhea , vomit ) , liver kidney disease , gastric bypass , gastric stapling , use Lapband , condition know interfere absorption , distribution , metabolism , excretion dietary supplement . History active neurological , endocrine , cardiovascular , pulmonary , hematological , immunologic/ autoimmune , psychiatric , metabolic disease consider clinically significant PI . Recent history ( within past 12 month ) , strong potential , alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5.0 oz wine , 1.5 oz distil spirit ) . Exposure investigational agent drug product within 30 day prior study entry . Subjects physical disability could interfere ability perform functional performance measure include protocol . Individual condition Investigator believe would interfere ability provide inform consent comply study instruction , might confound interpretation study result put patient undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>